Mobile Site ›

The Classic Myeloproliferative Neoplasms

Optimizing Laboratory Testing for Hematologic Disorders Series

JAK2 V617F Background

Slide 11

October 2011

Conversely, if the JAK2 V617F mutation is absent, it’s usually not helpful diagnostically. However, the absence of the V617F mutation does argue against a diagnosis of PV or the end-stage of PV, postpolycythemic myelofibrosis. JAK2 V617F is absent in CML, in secondary erythrocytosis, reactive thrombocytosis and leukocytosis, solid tumors, and in lymphoid disorders.

JAK2 V617F Background


Jump to section: